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Abstract: Intraoperative hyperglycemia has been observed to be
associated with increased morbidity and mortality after cardiac
surgery. Dextrose cardioplegia is used for its cardioprotective
effects but may lead to intraoperative hyperglycemia and more
postoperative complications. This was a retrospective observational study. Patient records (n = 2301) were accessed from a
large database at a tertiary care facility. The two groups (dextrose vs. nondextrose) were then matched using preoperative
variables of age, sex, body mass index, wound exposure time,
preoperative HbA1c levels, renal failure, hypertension, and
prior cerebrovascular disease. The following outcomes were

recorded: 30-day mortality, sternal wound infection, stroke, and
highest glucose level on cardiopulmonary bypass. The dextrose
cardioplegia group showed statistically higher intraoperative
glucose levels (272.76 ± 55.92 vs. 182.79 ± 45, p value = .0001).
There was no difference in postoperative mortality, sternal
wound infections or stroke incidence, nor in other secondary
outcomes. The type of cardioplegia solution was shown to
affect glucose levels; however, there was no effect on postoperative complication rates. Keywords: hyperglycemia, cardiac
surgery, postoperative complications, stroke, cardiac anesthesia.
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The development of blood cardioplegia and retrograde
delivery has improved the ability of surgeons to minimize
myocardial ischemia and enhance postoperative myocardial
function, yet there is considerable controversy regarding the
most efficient solution to minimize damage to the myocardium during the ischemic period. Surgeons tend to consistently use a particular type and composition of cardioplegic
solution based on personal preference (1).
Recently, an observational study using multivariate
logistic regression analysis for diabetics undergoing cardiac
surgery found that patients with better intraoperative
glucose control were found to have less mortality and
morbidity (2). Another study found that better control of
hyperglycemia led to a reduction in sternal wound infec-

tion (3). Van den Berghe et al.’s 2001 study (4) showed a
reduction in mortality, renal failure, and mechanical ventilation when intensive insulin therapy was used to control
glucose concentration postoperatively. Conversely, two
studies of tight glucose control, Gandhi et al. (5) (during
cardiac surgery) and a second Van den Berghe et al. (6)
(intensive care unit patients), resulted in slight increases
in mortality.
The objective of this study was to examine the effects
of two cardioplegia solutions (dextrose vs. nondextrose)
on patient outcomes such as mortality, incidence of deep
sternal wound infection, and cerebral vascular accidents as well as other clinical outcomes. The goal was
to determine whether adverse outcomes were greater in
either group.
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METHODS
Patient Selection
Adult cardiac surgery data from a large tertiary care
facility operating in the New York metropolitan area
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were retrospectively analyzed. Facility data from both the
New York State Cardiac Surgery Reporting System (CSRS)
and the Society of Thoracic Surgeons (STS) database were
used to compare key outcome variables between patients
who received cardioplegia solution with dextrose (n = 540)
vs. those who received cardioplegia solution without dextrose (n = 1761) (7,8). Specifically, the dextrose solution
contained 670 cc of normal saline, 30 g of dextrose, 60 mEq
of potassium chloride, and 100 mL of tromethamine
.6 Molar. The nondextrose solution contained 500 mL of
Isolyte-S, 22 mEq of sodium bicarbonate, 100 mg of lidocaine, and 30 mEq of potassium chloride. Both solutions
were administered using a 4:1 blood-to-crystalloid ratio.
Consecutive patients who underwent cardiac surgery with
cardioplegia between May 2007 and December 2009 were
selected for inclusion, yielding a total of 2301 individual
cases. Patients undergoing cardiac surgery who did not
receive a form of cardioplegia were excluded from the
study. Patients who had procedures not using cardiopulmonary bypass were specifically excluded. This study was
approved by the Institutional Review Board.
Preoperative Matching Variables
To enable direct comparison of the dextrose and
nondextrose groups, propensity score matching was used
(9). The following variables, partially chosen from the
Euroscore risk assessment and the CSRS and STS databases, were used to equate the two groups: body mass
index (BMI), HbA1c, pre-op creatine, ejection fraction,
wound exposure time, diabetes mellitus, hypertension,
chronic obstructive pulmonary disease, cerebrovascular
disease, myocardial infarction, congestive heart failure,
peripheral vascular disease, extensive aortic atherosclerosis, unstable shock, previous coronary artery bypass
grafting (CABG) or other heart surgery, current CABG
surgery, and current valve surgery.
Postoperative Outcome Variables
The primary outcome variables in this study were: mortality, deep sternal wound infection, cerebral vascular accident intraoperative up to 24 hours, and postoperative
cerebral vascular accident greater than 24 hours. Mortality
was defined as 30-day mortality; this term included patients
who died after discharge from the hospital but within
30 days of surgery and patients who died in the hospital
after 30 days. Deep sternal wound infection was defined as
drainage of purulent material from the sternotomy wound
and instability of the sternum within 6 months of surgery.
Cerebral vascular accident was identified as a new focal
neurologic deficit not including a transient ischemic attack.
Secondary outcome variables were: 30-day renal failure rate, leg infection, sepsis, transient ischemic attack,
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prolonged ventilation, reoperation for bleeding, dialysis,
and mean peak glucose on bypass. Mean peak glucose on
bypass was determined every 30 minutes on cardiopulmonary bypass sampling from the pump, both arterial and
venous, samples and measured in mg/dL.
Intraoperative Management
Intraoperative management differed only with respect
to the cardioplegia solution that was given. Mean arterial
pressure (MAP) was targeted for most patients on bypass
between 50 and 80 mmHg. Higher MAP was targeted for
patients with pre-existing neurologic disease and advanced
age (older than 80 years). Neurologic disease was defined
as a history of stroke or angiographic evidence or a 50%
narrowing in a major cerebral or carotid artery (common
or internal) or previous surgery for such disease. Blood
hematocrits were maintained above 21% on bypass.
Patients were put on insulin infusions (250 units in 250 mL
of normal saline) if blood glucose rose above 180 mg/dL at
any time during the procedure. Blood glucoses were targeted
for maintenance between 120 mg/dL and 160 mg/dL in
all patients. Blood glucoses that fell below that range
resulted in termination of the insulin infusion. Anesthetic
management of the patient varied depending on the anesthesia practitioner. In general, a mixture of sufentanil
and versed and volatile anesthetic was used. Isoflurane
was used on pump. Some practitioners preferred a continuous propofol infusion in lieu or in addition to the
volatile agent.
Statistical Methods
Because this was a nonrandomized retrospective cohort
study, it was necessary to match patients who received
cardioplegia solution with dextrose to those who did not.
This was accomplished using propensity score matching
used by statisticians who were not aware of the hypothesis.
This method enabled direct comparison of the dextrose
and nondextrose groups by simultaneously matching on a
number of confounding variables.
Comparability of the two groups before and after matching was evaluated using the two-sample t test for continuous
variables and the chi-square test or Fisher’s exact test, as
deemed appropriate, for categorical variables. Summary
statistics in Table 1 are reported as mean, standard deviation, and median (first quartile, third quartile) in their original units after matching.
Four hundred eighty-six matched pairs were identified
from the original database (a total of 972 patients). It
should be noted that propensity score matching yielded
matches for 90% of patients.
A result was considered statistically significant at the p <
.05 level. However, to adjust for multiple testing, a primary
outcomes result was considered significant only if p < .0125
JECT. 2012;44:134–138
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Table 1. Comparability of the groups after matching.
Variable
Age (years)*
BMI (kg/m2)*
HbA1c (%)*
HbA1c < 7
Preoperative creatinine (mg/dL)*
EF (%)*
Wound exposure time (in minutes)*
Gender (% male)
Race (% white)
DM
HTN
COPD
CVD
MI within 1–7 days
Current CHF
PVD
Extensive aortic atherosclerosis
Unstable shock
Previous CABG
Any other previous surgery
Current CABG surgery
Current valve surgery

Unexposed (nondextrose) (n = 486)

Exposed (dextrose) (n = 486)

66.77 ± 12.50
68.00 (59.00, 76.00)
28.50 ± 5.57
27.57 (24.93, 31.30)
6.29 ± 1.40
6.00 (5.50, 6.60)
285 (58.64%)
1.30 ± 1.06
1.10 (.90, 1.30)
49.69 ± 13.81
55.00 (40.00, 60.00)
312.93 ± 96.09
292.50 (244.00, 370.00)
342 (70.37%)
380 (78.19%)
168 (34.57%)
382 (78.60%)
144 (29.63%)
65 (13.37%)
44 (27.16%)
161 (33.13%)
66 (13.58%)
55 (11.32%)
13 (2.67%)
22 (4.53%)
13 (2.67%)
307 (63.17%)
282 (58.02%)

67.39 ± 13.49
69.00 (59.00, 79.00)
28.05 ± 5.32
27.47 (24.39, 31.16)
6.24 ± 1.26
5.90 (5.50, 6.50)
302 (62.14%)
1.35 ± 1.28
1.00 (.90, 1.30)
50.40 ± 12.51
53.00 (45.00, 60.00)
311.49 ± 90.57
298.00 (243.00, 364.00)
332 (68.31%)
373 (76.75%)
154 (31.69%)
375 (77.16%)
153 (31.48%)
73 (15.02%)
45 (29.41%)
166 (34.16%)
61 (12.55%)
52 (10.70%)
11 (2.26%)
25 (5.14%)
13 (2.67%)
300 (61.73%)
254 (52.26%)

p Value
.4551
.1973
.5593
.7378
.4743
.3998
.8100
.4866
.5234
.3401
.5885
.5309
.4622
.4229
.7343
.6342
.7585
.6793
.6537
1.0000
.6429
.0710

*Data are reported as mean, standard deviation, and median (first quartile, third quartile), and are analyzed using the two-sample t test.
BMI, body mass index; EF, ejection fraction; DM, diabetes mellitus; HTN, hypertension; COPD, chronic obstructive pulmonary disease;
CVD, cerebrovascular disease; MI, myocardial infarction; CHF, congestive heart failure; PVD, peripheral vascular disease.

(Bonferroni adjustment, .0125 = .05/4). No adjustments
were made for secondary outcomes. The widths of the confidence intervals for differences in rates (Table 2) are provided for insights into the precision of the results.

RESULTS
All rates were in the average range as reported by the
New York State Department of Health (NYSDOH) during

Table 2. Matched pairs analyses of primary and secondary outcomes.

Mortality (30-day)
Sternal wound infection
Renal failure
Leg infection that requires excision of tissue, positive blood
cultures, or treatment with antibiotics
Sepsis
Transient ischemic attack
Cerebral vascular accident (CVA) intraoperative less than
24 hours
CVA greater than 24 hours
Prolonged ventilation
Reoperation for bleeding
New dialysis
Postoperative Day #1, 6 AM glucose (mg/dL)†
Postoperative Day #2, 6 AM glucose (mg/dL)‡
Highest glucose on bypass (mg/dL)§

n

Unexposed
(nondextrose)

Exposed
(dextrose)

Difference and 95% Confidence
Interval for Difference

p Value

486
486
486
486

24 (4.94%)
6 (1.23%)
19 (3.91%)
5 (1.03%)

19 (3.91%)
4 (.82%)
14 (2.88%)
3 (.62%)

1.03 (–1.47 to 3.53)
.41 (–.89 to 1.71)
1.03 (–1.26 to 3.32)
.41 (–.75 to 1.58)

.5114
.7539
.4731
.7266

486
486
486

8 (1.65%)
2 (.41%)
4 (.82%)

12 (2.47%)
1 (1.21%)
2 (.41%)

–.82 (–2.66 to 1.02)
.21 (–.51 to .92)
.41 (–.60 to 1.42)

.5034
1.0000
.6875

486
486
486
486
361
351
485

5 (1.03%)
75 (15.43%)
15 (3.09%)
18 (3.70%)
125.38 ± 27.69
130.22 ± 28.22
182.79 ± 45.98

5 (1.03%)
70 (14.40%)
8 (1.65%)
11 (2.26%)
123.62 ± 26.19
129.78 ± 26.56
272.76 ± 55.92

.00 (–1.30 to 1.30)
1.03 (–3.42 to 5.48)
1.44 (–.53 to 3.41)
1.44 (–.70 to 3.58)
–1.76 (–5.60 to 2.08)
–.44 (–4.53 to 3.64)
89.98 (83.65 to 96.30)

1.0000
.7117
.2100
.2478
.2817*
.7681*
<.0001*

*Data were analyzed using the paired t test.
†Standard deviation (SD) of the mean difference for the paired analysis = 37.13.
‡SD of the mean difference for the paired analysis = 38.94.
§D of the mean difference for the paired analysis = 70.91.
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Figure 1. Glucose (mg/dL) during bypass and first and second days
after bypass.

this time period (10). No significant differences were found
between groups for any outcomes of this study. Specifically:
 The postoperative deep sternal wound infection rate
was 1.23% in the nondextrose group and .82% in the
dextrose group.
 The cerebral vascular accident rates within 24 hours
of surgery were .82% in the nondextrose group and
.41% in the dextrose group.
 The cerebral vascular accident rates after 24 hours were
1.03% in each of the two groups.
 Mortality was 4.94% in the nondextrose group and
3.91% in the dextrose group.
 The postoperative new dialysis rate, defined as a patient
who had never been dialyzed preoperatively or dialyzed
once but required dialysis postoperatively, was 3.70% in
the nondextrose group vs. 2.26% in the dextrose group.
As may be expected, the highest peak glucose on bypass
was significantly higher in the dextrose group (272.76 ±
55.92 vs. 182.79 ± 45, p value = .0001). However, on the
first postoperative day (POD #1 6 AM), dextrose levels
were similar in both groups (125.38 ± 27.69 vs. 123.62 ±
26.19). On the second postoperative day (POD #2 6 AM),
dextrose levels were also similar (130.22 ± 28.22 vs. 129.78 ±
26.56; Figure 1). The well-controlled postoperative glucoses
reflect an intensive insulin protocol in which all patients are
placed on arrival to the cardiothoracic intensive care unit.
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who received dextrose cardioplegia and those who did
not. Because we controlled for a number of key variables
that would potentially impact the cerebrovascular accident
rate, we had expected the higher glucose group to have a
higher rate. Nevertheless, the rate did not differ between
the groups. Other studies have found results similar to the
results reported herein (11,12).
In this study, both groups exhibited a rather low deep
sternal wound infection rate. The authors were surprised
by this finding, because the dextrose group had higher
glucose levels on bypass. Prior research has shown an
increase in deep sternal wound infections when blood
glucose was above 200 mg/dL through POD 2 (3,13). A
contributing factor to the low deep sternal wound infection rates may be that the average BMI was relatively low
(28 kg/m2) in each cohort. Aggressive insulin management
postoperatively may also have contributed to the low incidence in both groups.
Postoperative ventilation and mortality were not statistically different between the groups. This finding is not consistent with prior research done by Doenst et al. (2) and
Ouattara et al. (14), which show that peak glucose levels on
bypass was independently associated with increased mortality and morbidity in both diabetics and nondiabetics.
Aggressive management in the cardiothoracic unit may
have prevented complications. Long-term control of glucose levels or elevated preoperative HbA1c levels may be
more important for morbidity and mortality after cardiac
surgery rather than short-term hyperglycemia (15).
Strengths and Limitations
Although this study used a well-designed quasiexperimental approach, all factors that might affect the
blood glucose level intraoperatively could not be controlled
for. Hypothermia, for example, may account for variance in
insulin resistance and, hence, glucose levels (16).
It should also be acknowledged that implementation of
an appropriate randomized trial would be impractical given
surgeon preferences with respect to the cardioplegia used.
A strength of this study was the use of a validated database: New York State CSRS data are validated internally
before submission to the NYSDOH. In addition, records
are randomly audited by the NYSDOH.
Finally, sample size and statistical approach was a strength
of the study. The use of propensity score matching of various preoperative risk factors did indeed achieve uniformity
in the two groups.

DISCUSSION

CONCLUSION

The aim of this study was to observe outcomes for
patients receiving cardioplegic solutions with and without
dextrose. This study did not find a significant difference in
cerebral vascular accident rate between those patients

This study suggests that the use of dextrose cardioplegia
is not detrimental on key outcome variables such as
deep sternal would infection, cerebral vascular accident
rate, and mortality in conjunction with aggressive insulin
JECT. 2012;44:134–138
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management, intra- and postoperatively, and good blood
glucose control. A large randomized clinical trial may
confirm or refute this conclusion.
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